SciSparc & Clearmind Patent Application for MDMA Treatment
Ticker: SPRC · Form: 6-K · Filed: Sep 6, 2024 · CIK: 1611746
| Field | Detail |
|---|---|
| Company | Scisparc Ltd. (SPRC) |
| Form Type | 6-K |
| Filed Date | Sep 6, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: patent, collaboration, psychedelics, pharmaceuticals
TL;DR
SciSparc and Clearmind filed a patent for an MDMA combo treatment - big news for psychedelics!
AI Summary
On September 6, 2024, SciSparc Ltd. announced a collaboration with Clearmind Medicine that has led to the publication of an international patent application. This application covers an innovative MDMA-based combination treatment, potentially for various medical conditions.
Why It Matters
This patent application signifies progress in developing novel therapeutic approaches using MDMA, which could lead to new treatment options for conditions currently lacking effective therapies.
Risk Assessment
Risk Level: medium — The filing is a patent application publication, which is a positive step but does not guarantee market approval or commercial success.
Key Players & Entities
- SciSparc Ltd. (company) — Filer of the report and collaborator
- Clearmind Medicine (company) — Collaborator on the patent application
- September 6, 2024 (date) — Date of the press release
- MDMA (drug) — Active component in the patented treatment
FAQ
What is the specific nature of the innovative MDMA-based combination treatment?
The filing states it is an 'innovative MDMA-based combination treatment' but does not provide specific details on the combination or the intended medical conditions in this report.
What is the status of the international patent application?
The international patent application has been published as of September 6, 2024.
What is the relationship between SciSparc Ltd. and Clearmind Medicine?
SciSparc Ltd. and Clearmind Medicine are collaborators on this patent application.
When was this information officially announced by SciSparc Ltd.?
The information was announced via a press release issued on September 6, 2024.
Does this filing indicate regulatory approval for the treatment?
No, this filing is a report of a published international patent application and does not indicate any regulatory approval for the treatment.
Filing Stats: 336 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-09-06 08:15:31
Filing Documents
- ea0213580-6k_scisparc.htm (6-K) — 13KB
- ea021358001ex99-1_scisparc.htm (EX-99.1) — 9KB
- 0001213900-24-076293.txt ( ) — 23KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SciSparc Ltd. Date: September 6, 2024 By: /s/ Oz Adler Name: Oz Adler Title: Chief Executive Officer and Chief Financial Officer 3